Karthik and her team aimed to use CRISPR as a way to identify and isolate a protein generated by the bacteria that cause Lyme ...
Chicago-based CRISPR technology company Syntax Bio says it has developed tech which automates the slow, manual process of ...
Morning Overview on MSN
Programmable CRISPR cuts stem cell timing from months to weeks
Programmable CRISPR tools are turning stem cell biology into something closer to software engineering, shrinking ...
Investor's Business Daily on MSN
Stocks to watch: CRISPR Therapeutics sees relative strength rating rise to 82
CRISPR Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 82.
Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...
Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of new research in Science Advances detailing the company’s CRISPR-based ...
Syntax Bio, a synthetic biology company programming the next generation of cell therapies, has published new research in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback